Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of enterococcal infections

INTRODUCTION

Enterococcal species can cause a variety of infections, including urinary tract infections, bacteremia, endocarditis, and meningitis. The antimicrobial agents available for treatment of enterococcal infection are reviewed here, followed by treatment approaches for clinical syndromes caused by enterococci. Other issues related to enterococci are discussed in detail separately. (See "Mechanisms of antibiotic resistance in enterococci" and "Epidemiology, prevention and control of vancomycin-resistant enterococci" and "Microbiology of enterococci".)

CLINICAL APPROACH

Approach to susceptible strains — Compared with most streptococci, enterococci are relatively resistant to penicillin and ampicillin; even when these cell wall–active agents inhibit enterococci, they often do not kill them, and vancomycin is even less bactericidal. Enterococcus faecium isolates are more resistant to penicillin than E. faecalis (minimum inhibitory concentration for 90 percent of strains [MIC90] >16 mg/mL versus 2 to 4 mcg/mL, respectively); MICs for ampicillin are usually 1 dilution lower than those of penicillin. Piperacillin activity is similar to that of penicillin, and imipenem has some activity against E. faecalis. Cell wall–active agents with limited or no activity against enterococci include nafcillin, oxacillin, ticarcillin, ertapenem, most cephalosporins, and aztreonam.

Enterococci are also relatively impermeable to aminoglycosides, and the serum concentrations of aminoglycosides required for bactericidal activity are much higher than can be achieved safely in humans. However, the simultaneous use of a cell wall–active agent raises the permeability of the cell so that an intracellular bactericidal aminoglycoside concentration can be achieved without excessive toxicity [1]. Bactericidal activity is warranted in clinical circumstances of life-threatening infection. (See 'Clinical infections' below.)

Enterococcal isolates are usually tested for susceptibility to ampicillin, penicillin, and vancomycin. Although found only rarely, the presence of beta-lactamase confers resistance to penicillin and ampicillin when large numbers of organisms are present (eg, endocarditis vegetation), even though the organism may test susceptible using standard laboratory inocula. Thus, to rule out this possibility for endocarditis or other life-threatening enterococcal infections, such as meningitis, some experts recommend that the isolate be screened for beta-lactamase production with nitrocefin, a chromogenic cephalosporin, even if ampicillin susceptible.

Traditionally, the standard of care for enterococcal endocarditis has been a cell wall–active agent combined with an aminoglycoside to generate synergistic, bactericidal activity. When an aminoglycoside is used, the enterococcal isolates should be tested for high-level resistance to gentamicin and streptomycin. If the organism is reported as susceptible to high levels of an aminoglycoside ("SYN-S" indicates "susceptible to synergism"), then it is assumed that synergism will be achieved when that aminoglycoside is combined with ampicillin. Strains that are resistant to high levels of gentamicin are resistant to synergism with tobramycin, netilmicin, and amikacin as well as gentamicin, but some of these strains lack high-level resistance to streptomycin and these will demonstrate synergism with that agent [2,3]. (See 'Clinical infections' below.)

                      

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Oct 2014. | This topic last updated: Sep 3, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.
  2. Caballero-Granado FJ, Cisneros JM, Luque R, et al. Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas. J Clin Microbiol 1998; 36:520.
  3. Antalek MD, Mylotte JM, Lesse AJ, Sellick JA Jr. Clinical and molecular epidemiology of Enterococcus faecalis bacteremia, with special reference to strains with high-level resistance to gentamicin. Clin Infect Dis 1995; 20:103.
  4. Treatment Guidelines. Med Lett 2007; 57:33.
  5. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. Clin Infect Dis 2013; 56:1261.
  6. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000; 342:710.
  7. Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995; 1:249.
  8. Dodge RA, Daly JS, Davaro R, Glew RH. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multiresistant enterococci. Clin Infect Dis 1997; 25:1269.
  9. Gavaldà J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43:639.
  10. Gavaldà J, Len O, Miró JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.
  11. Wilson DN, Schluenzen F, Harms JM, et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci U S A 2008; 105:13339.
  12. Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50:2500.
  13. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64:1506.
  14. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343.
  15. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36:159.
  16. El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis 2003; 5:121.
  17. Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003; 37:e29.
  18. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.
  19. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.
  20. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.
  21. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.
  22. Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.
  23. Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.
  24. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006; 66:595.
  25. Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.
  26. Sakoulas G, Rose W, Nonejuie P, et al. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2014; 58:1494.
  27. Sakoulas G, Bayer AS, Pogliano J, et al. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 2012; 56:838.
  28. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63.
  29. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 2006; 58:1208.
  30. Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36:2611.
  31. Munita JM, Mishra NN, Alvarez D, et al. Failure of High-Dose Daptomycin for Bacteremia Caused by Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions. Clin Infect Dis 2014; 59:1277.
  32. Munita JM, Tran TT, Diaz L, et al. A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 2013; 57:2831.
  33. Munita JM, Panesso D, Diaz L, et al. Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother 2012; 56:4354.
  34. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245.
  35. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.
  36. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26:511.
  37. Ward KE, Mersfelder TL, LaPlante KL. Oritavancin--an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006; 15:417.
  38. Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 2014; 370:2180.
  39. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm408475.htm (Accessed on August 07, 2014).
  40. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50:3479.
  41. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47:216.
  42. Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44:3022.
  43. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.
  44. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5:S341.
  45. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704.
  46. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007; 2:343.
  47. Schutt AC, Bohm NM. Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 2009; 43:2108.
  48. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010; 29:379.
  49. Batts DH, Lavin BS, Eliopoulos GM. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report. Curr Clin Top Infect Dis 2001; 21:227.
  50. Collins LA, Malanoski GJ, Eliopoulos GM, et al. In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 1993; 37:598.
  51. Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 2002; 46:1845.
  52. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999; 44:251.
  53. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004; 53:646.
  54. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2:ii5.
  55. Baptista M, Depardieu F, Reynolds P, et al. Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci. Mol Microbiol 1997; 25:93.
  56. Kawalec M, Gniadkowski M, Kedzierska J, et al. Selection of a teicoplanin-resistant Enterococcus faecium mutant during an outbreak caused by vancomycin-resistant enterococci with the vanB phenotype. J Clin Microbiol 2001; 39:4274.
  57. Bérenger R, Bourdon N, Auzou M, et al. In vitro activity of new antimicrobial agents against glycopeptide-resistant Enterococcus faecium clinical isolates from France between 2006 and 2008. Med Mal Infect 2011; 41:405.
  58. Draghi DC, Benton BM, Krause KM, et al. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008; 62:116.
  59. Krause KM, Renelli M, Difuntorum S, et al. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:2647.
  60. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int J Antimicrob Agents 2010; 35:451.
  61. Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005; 41:1134.
  62. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. South Med J 2003; 96:818.
  63. Bethea JA, Walko CM, Targos PA. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 2004; 38:989.
  64. Matsumura S, Simor AE. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 1998; 27:1554.
  65. Raad I, Hachem R, Hanna H, et al. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. Antimicrob Agents Chemother 2001; 45:3202.
  66. Tripodi MF, Locatelli A, Adinolfi LE, et al. Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci. Eur J Clin Microbiol Infect Dis 1998; 17:734.
  67. Safdar A, Bryan CS, Stinson S, Saunders DE. Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline. Clin Infect Dis 2002; 34:E61.
  68. Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis 1994; 20:41.
  69. Howe RA, Robson M, Oakhill A, et al. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother 1997; 40:144.
  70. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27:1259.
  71. Norris AH, Reilly JP, Edelstein PH, et al. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995; 20:1137.
  72. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760.
  73. Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990; 3:46.
  74. Hamilton-Miller JM. Reversal of activity of trimethoprim against gram-positive cocci by thymidine, thymine and 'folates'. J Antimicrob Chemother 1988; 22:35.
  75. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34:1792.
  76. Goodhart GL. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 1984; 252:2748.
  77. Anonymous. National Nosocomial Infections Surveillance (NNIS) report, data summary from January 1990 to May 1999, Issued June 1999. Am J Infect Control 1999; 520:532.
  78. National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986-April 1998, issued June 1998. Am J Infect Control 1998; 26:522.
  79. Jones RN, Kugler KC, Pfaller MA, Winokur PL. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagn Microbiol Infect Dis 1999; 35:55.
  80. Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis 1983; 148:57.
  81. Lai KK. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996; 156:2579.
  82. Minassian MA, Lewis DA, Chattopadhyay D, et al. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10:39.
  83. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53:637.
  84. Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 43:211.
  85. Onrust SV, Lamb HM, Balfour JA. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs 1998; 56:895.
  86. Malinverni R, Glauser MP. Comparative studies of fluoroquinolones in the treatment of urinary tract infections. Rev Infect Dis 1988; 10 Suppl 1:S153.
  87. Corrado ML, Hesney M, Struble WE, et al. Norfloxacin versus trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. Eur Urol 1990; 17 Suppl 1:34.
  88. Zervos MJ, Bacon AE 3rd, Patterson JE, et al. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother 1988; 21:113.
  89. Tice AD. Short-course therapy of acute cystitis: a brief review of therapeutic strategies. J Antimicrob Chemother 1999; 43 Suppl A:85.
  90. Stannard AJ, Sharples SJ, Norman PM, Tillotson GS. Ciprofloxacin therapy of urinary tract infections in paraplegic and tetraplegic patients: a bacteriological assessment. J Antimicrob Chemother 1990; 26 Suppl F:13.
  91. Malathum K, Singh KV, Murray BE. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteria. Diagn Microbiol Infect Dis 1999; 35:127.
  92. Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. J Antimicrob Chemother 1996; 37:1011.
  93. Martínez-Martínez L, Joyanes P, Pascual A, et al. Activity of eight fluoroquinolones against enterococci. Clin Microbiol Infect 1997; 3:497.
  94. Gray J, Marsh PJ, Stewart D, Pedler SJ. Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect 1994; 27:179.
  95. Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67:248.
  96. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74:191.
  97. Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis. Clin Infect Dis 1992; 15:49.
  98. Shlaes DM, Levy J, Wolinsky E. Enterococcal bacteremia without endocarditis. Arch Intern Med 1981; 141:578.
  99. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584.
  100. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239.
  101. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.
  102. Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72.
  103. Gullberg RM, Homann SR, Phair JP. Enterococcal bacteremia: analysis of 75 episodes. Rev Infect Dis 1989; 11:74.
  104. Hoge CW, Adams J, Buchanan B, Sears SD. Enterococcal bacteremia: to treat or not to treat, a reappraisal. Rev Infect Dis 1991; 13:600.
  105. Watanakunakorn C, Patel R. Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin. Clin Infect Dis 1993; 17:74.
  106. Stevenson KB, Murray EW, Sarubbi FA. Enterococcal meningitis: report of four cases and review. Clin Infect Dis 1994; 18:233.
  107. Bayer AS, Seidel JS, Yoshikawa TT, et al. Group D enterococcal meningitis. Clinical and therapeutic considerations with report of three cases and review of the literature. Arch Intern Med 1976; 136:883.
  108. Kurup A, Tee WS, Loo LH, Lin R. Infection of central nervous system by motile Enterococcus: first case report. J Clin Microbiol 2001; 39:820.
  109. Buchino JJ, Ciambarella E, Light I. Systemic group D streptococcal infection in newborn infants. Am J Dis Child 1979; 133:270.
  110. Siegel JD, McCracken GH Jr. Group D streptococcal infections. J Pediatr 1978; 93:542.
  111. Nagai K, Yuge K, Ono E, et al. Enterococcus faecium meningitis in a child. Pediatr Infect Dis J 1994; 13:1016.
  112. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008; 61:461.
  113. Williamson JC, Glazier SS, Peacock JE Jr. Successful treatment of ventriculostomy-related meningitis caused by vancomycin-resistant Enterococcus with intravenous and intraventricular quinupristin/dalfopristin. Clin Neurol Neurosurg 2002; 104:54.
  114. Nachman SA, Verma R, Egnor M. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: an antibiotic cure. Microb Drug Resist 1995; 1:95.
  115. Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998; 26:1460.
  116. Garey KW, Tesoro E, Muggia V, et al. Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant Enterococcus faecium [correction of faecalis] ventriculitis. Pharmacotherapy 2001; 21:748.
  117. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001; 33:375.
  118. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001; 33:477.
  119. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002; 21:798.
  120. Hachem R, Afif C, Gokaslan Z, Raad I. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001; 20:432.
  121. Steinmetz MP, Vogelbaum MA, De Georgia MA, et al. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001; 29:2383.
  122. Ryan JL, Pachner A, Andriole VT, Root RK. Enterococcal meningitis: combined vancomycin and rifampin therapy. Am J Med 1980; 68:449.
  123. Pérez Mato S, Robinson S, Bégué RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr Infect Dis J 1999; 18:483.
  124. Venezio FR, Masters D, O'Keefe P. Enterococcal meningitis: failure of treatment with ampicillin and chloramphenicol. J Infect Dis 1984; 150:305.